NCT02063607View on ClinicalTrials.gov

The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

July 31, 2016

Conditions
Hepatitis C
Interventions
BIOLOGICAL

Peginterferon lambda

Trial Locations (1)

10000

The Military 108 Hospital, Hanoi

Sponsors
All Listed Sponsors
lead

Nanogen Pharmaceutical Biotechnology Joint Stock Company

INDUSTRY

NCT02063607 - The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients | Biotech Hunter | Biotech Hunter